NCOA5 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblast cell line. This product features targeted disruption of the NCOA5 gene via CRISPR/Cas9, generating a heterogeneous pool of knockout alleles. The polyclonal format avoids clonal selection biases and enables robust population-level functional analyses. These cells serve as a loss-of-function model to investigate the transcriptional coregulator NCOA5 in a B cell context, without necessitating single-cell cloning.
The Raji parental line is an EBV-immortalized B lymphoblastoid cell line isolated from a Burkitt??s lymphoma patient. It displays characteristic B cell surface markers and retains features of aggressive B cell malignancy, making it a widely employed model for studies of B cell biology, lymphomagenesis, and EBV-driven oncogenesis. The lymphoblastoid phenotype maintains expression of lymphoid-specific transcription factors, providing a physiologically relevant platform to study NCOA5 function in hematopoietic malignancies.
NCOA5 operates as a transcriptional coactivator that bridges sequence-specific transcription factors??including estrogen receptor alpha (ER??), thyroid hormone receptor beta (TR??), and forkhead box O1 (FOXO1)??with the core transcriptional machinery, such as RNA polymerase II and the Mediator complex. Upon activation by estrogen-bound ER?? or thyroid hormone-bound TR, NCOA5 interacts with cofactors like CBP/p300 and ERR?? to drive expression of targets such as TFF1 and GREB1. In metabolic pathways, FOXO1 recruits NCOA5 and PGC-1?? to promoters of gluconeogenic enzymes including G6PC and PCK1, integrating hormonal signals with metabolic gene output. NCOA5 also engages with other nuclear receptors, serving as a hub for diverse signaling inputs.
In the Raji B lymphoblast environment, knockout of NCOA5 permits dissection of its contributions to B cell transcriptional programs and lymphoma biology. The EBV-positive background raises the possibility that NCOA5 modulates viral-host interactions or oncogenic transcriptional networks; disruption may reveal phenotypes related to proliferation, apoptosis, or drug sensitivity. This polyclonal knockout population also allows comparative analyses with breast cancer or hepatocellular carcinoma models, where NCOA5??s role in hormone signaling and metabolic dysregulation is established.
These knockout cells enable nuclear receptor reporter assays, RNA-seq, and ChIP-qPCR to map NCOA5 target loci. Co-immunoprecipitation can examine interactions with ER??, TR??, FOXO1, or Mediator. Functional studies, including proliferation, flow cytometry for cell cycle and apoptosis, and drug sensitivity assays, evaluate NCOA5??s impact on lymphoma phenotypes. Researchers in cancer biology, endocrinology, and drug discovery will find this model valuable. For technical support, contact Ascent Research.
